Peptides Similar to Survodutide

Peptides Related to Survodutide#

Survodutide (BI 456906) belongs to the emerging class of multi-receptor metabolic peptide agonists that leverage combinations of incretin and glucagon signaling pathways to treat obesity and related metabolic diseases. As a dual glucagon/GLP-1 receptor agonist, survodutide occupies a distinct pharmacological position among these agents. The following comparison examines the most clinically relevant compounds in this therapeutic landscape, evaluating their mechanisms, clinical outcomes, development status, and differentiated features.

Tirzepatide (Mounjaro / Zepbound)#

Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved as Mounjaro (2022) for type 2 diabetes and Zepbound (2023) for chronic weight management. It is a 39-amino-acid peptide based on the native GIP backbone with an Aib substitution at position 2 for DPP-4 resistance and a C20 fatty diacid at Lys20 for albumin binding, providing a half-life of approximately 5 days and once-weekly dosing.

Mechanism comparison: Tirzepatide activates GIP and GLP-1 receptors, while survodutide activates glucagon and GLP-1 receptors. This distinction is pharmacologically significant. Tirzepatide's GIP receptor component is hypothesized to enhance insulin sensitivity, improve beta-cell function, and modulate fat distribution. Survodutide's glucagon receptor component increases hepatic energy expenditure, promotes fatty acid beta-oxidation, and directly reduces hepatic lipid accumulation. Both molecules share GLP-1R-mediated appetite suppression and glucose-dependent insulin secretion, but their non-GLP-1 receptor components provide fundamentally different complementary metabolic effects.

Clinical efficacy comparison: Direct head-to-head trials between tirzepatide and survodutide have not been conducted. Cross-trial comparisons are inherently limited by differences in patient populations, trial designs, and treatment durations:

• Tirzepatide achieved weight loss of 15.0-22.5% at 72 weeks in the SURMOUNT-1 trial (obesity without diabetes, doses up to 15 mg weekly).
• Survodutide achieved weight loss of approximately 14.9% at 46 weeks in the COURAGE Phase 2 trial (obesity without diabetes, dose of 4.8 mg weekly).

The shorter treatment duration and Phase 2 design of the survodutide trial make direct numerical comparison unreliable. The ongoing Phase 3 ACHIEVE program for survodutide will provide data more suitable for cross-trial comparison, with longer treatment durations and optimized dosing.

MASH/liver disease data: This is a potential differentiating area for survodutide. The glucagon receptor component provides direct hepatic lipid oxidation that may offer advantages for MASH beyond weight loss alone. In the survodutide Phase 2b MASH trial, 47% of patients in the 4.8 mg group achieved MASH resolution without worsening fibrosis, with approximately 64% mean relative reduction in liver fat. While tirzepatide has shown improvements in hepatic steatosis markers, the direct hepatic effects of glucagon signaling may provide survodutide with a mechanistic advantage in MASH that will be tested in Phase 3 trials.

Development status: Tirzepatide is FDA-approved and commercially available for both type 2 diabetes and obesity. Survodutide remains investigational in Phase 3 trials. This difference is significant for clinical applicability: tirzepatide has an established prescribing framework, growing real-world evidence, and post-marketing safety surveillance, while survodutide's benefit-risk profile is still being characterized.

Retatrutide (LY3437943)#

Retatrutide is an investigational triple incretin receptor agonist developed by Eli Lilly that simultaneously activates GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical development for obesity, type 2 diabetes, and MASH.

Mechanism comparison: Retatrutide shares glucagon receptor activity with survodutide but adds GIP receptor agonism as a third mechanism. The GIP component is hypothesized to enhance insulin secretion, improve lipid metabolism, and modulate central appetite regulation through pathways distinct from GLP-1. In contrast, survodutide relies solely on GLP-1R activation for its non-glucagon metabolic effects. The triple versus dual agonist question represents one of the central pharmacological debates in the metabolic peptide field: whether three receptor activities produce synergistic benefits beyond dual agonism, or whether the additional complexity introduces diminishing returns or additional risks.

Clinical efficacy comparison: In the Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide achieved weight loss of approximately 24.2% at 48 weeks at the highest dose (12 mg weekly) in adults with obesity. This exceeds the 14.9% observed with survodutide at 46 weeks, though cross-trial comparison is limited by differences in dose levels, escalation schedules, and patient populations. Both molecules are in Phase 3 programs that will provide more definitive efficacy data.

Regarding MASH, retatrutide showed notable hepatic fat reductions in Phase 2, with over 80% of participants achieving hepatic steatosis resolution. Survodutide also demonstrated substantial liver fat reduction (approximately 64% relative decrease) in its Phase 2b MASH trial. Both molecules are pursuing MASH as a key therapeutic indication in Phase 3.

Safety considerations: Both survodutide and retatrutide share the gastrointestinal side effect profile common to incretin-based therapies. Both also carry theoretical concerns related to chronic glucagon receptor activation, including effects on hepatic glucose output, amino acid metabolism, and potential long-term hepatic effects. Retatrutide's additional GIP receptor activity may introduce unique considerations not present with survodutide's dual agonism. Long-term safety profiles for both molecules are not yet established.

Development status: Both survodutide and retatrutide are in Phase 3 clinical trials and are not yet approved by any regulatory authority. They represent competing approaches to the same therapeutic targets (obesity and MASH) from different pharmaceutical companies (Boehringer Ingelheim vs. Eli Lilly).

Semaglutide (Ozempic / Wegovy / Rybelsus)#

Semaglutide is a selective GLP-1 receptor agonist developed by Novo Nordisk, approved as Ozempic (2017) for type 2 diabetes and Wegovy (2021) for chronic weight management. An oral formulation (Rybelsus) is also approved for type 2 diabetes. Semaglutide is a 31-amino-acid GLP-1 analog with an Aib substitution at position 8 and a C18 fatty diacid at Lys26 for albumin binding, providing a half-life of approximately 7 days.

Mechanism comparison: Semaglutide activates only the GLP-1 receptor, while survodutide activates both glucagon and GLP-1 receptors. The absence of glucagon receptor activity in semaglutide means it lacks the direct hepatic thermogenic and lipid oxidation effects that are central to survodutide's differentiated mechanism. Semaglutide achieves weight loss primarily through appetite suppression and reduced caloric intake, without the energy expenditure enhancement provided by glucagon signaling.

Clinical efficacy comparison: Semaglutide 2.4 mg achieved approximately 14.9-16.0% weight loss at 68 weeks in the STEP trials. Survodutide achieved approximately 14.9% weight loss at 46 weeks in the COURAGE Phase 2 trial. The comparable magnitude of weight loss at a shorter time point suggests that survodutide may achieve greater total weight loss with longer treatment duration, though this remains to be confirmed in Phase 3 trials.

For MASH, semaglutide has shown improvements in hepatic steatosis and was evaluated in a Phase 2 trial for NASH. However, its mechanism of action for liver benefit is primarily indirect (through weight loss and metabolic improvement) rather than through direct hepatic lipid oxidation, which is a key pharmacological advantage that survodutide's glucagon component may provide.

Cardiovascular outcomes: Semaglutide has a substantial cardiovascular evidence advantage, with the SUSTAIN-6 trial demonstrating MACE reduction in type 2 diabetes and the SELECT trial demonstrating cardiovascular benefit in obesity without diabetes. Survodutide has no cardiovascular outcomes data, and such data are unlikely to be available until well after Phase 3 completion.

Dosing and convenience: Both agents are administered once weekly by subcutaneous injection. Semaglutide offers the additional option of a daily oral tablet (Rybelsus) for type 2 diabetes, though with lower bioavailability. Survodutide is available only as an investigational injectable formulation.

Cross-Class Comparison Summary#

Evidence Gaps in Comparative Assessment#

• No head-to-head clinical trials between survodutide and any comparator have been conducted or announced.
• Cross-trial comparisons are limited by differences in patient populations, trial designs, dose levels, escalation schedules, and treatment durations.
• The relative contribution of glucagon receptor agonism (survodutide) versus GIP receptor agonism (tirzepatide) to weight loss and metabolic improvement has not been directly compared.
• Long-term comparative effects on body composition, lean mass preservation, cardiovascular outcomes, and MASH histological endpoints remain unknown.
• The optimal receptor combination (dual GLP-1/GCGR, dual GIP/GLP-1, or triple GIP/GLP-1/GCGR) for different patient populations and disease states has not been established.

Related Reading#

• Survodutide overview and research guide
• Survodutide research evidence
• Survodutide dosing protocols